pharmacoresistant

pharmacoresistant

(for″mă-kō-ri-zis′tănt) [pharmaco- + resistant]
Not easily treated with drugs; drug resistant. The term is used to describe refractory infections or tumors.
pharmacoresistance (-zis′tăns)
Mentioned in ?
References in periodicals archive ?
A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period.
Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.
EpiMiRNA brings together experts on the neurobiology of miRNAs with the leading researchers working on miRNAs in epilepsy, epilepsy geneticists, leaders in miRNA-target detection, proteomics, and systems biology with research-intensive SMEs pursuing miRNA therapeutics and treatments for pharmacoresistant epilepsy.
Indicated for treatment of both pharmacoresistant epilepsy and treatment-resistant depression (TRD), VNS Therapy consists of a pacemaker-like device implanted in the chest that delivers mild pulsed signals to the brain via the vagus nerve in the neck.
1] Engel estimated that as of the early 1990s more than 8000 patients had undergone a surgical procedure as the definitive treatment for pharmacoresistant seizure disorder.
Recent research supports the notion that prolonged seizures become pharmacoresistant if not treated promptly.
The newly selected candidates, similar in molecular structure to retigabine, have demonstrated much greater potency and potential efficacy in pre-clinical models, including a model of pharmacoresistant epilepsy.
There is an ongoing need for effective and well-tolerated treatment options for people with pharmacoresistant epilepsy, particularly as many will try a range of drugs before finding one that works for them.
The results demonstrated that VNS Therapy improved Quality of Life and seizure rates compared to best medical management in patients with pharmacoresistant epilepsy.